If symptoms persist beyond three weeks, contact your healthcare provider about adjusting your dosage or trying alternative formulations through PlexusDx
In a 48-week phase 2 trial published in The New England Journal of Medicine , adults with obesity (without type 2 diabetes) receiving once-weekly subcutaneous retatrutide at the 12 mg amount achieved a least-squares mean body weight reduction of 24.2%, compared with 2.1% in the placebo group [1]
Contact our customer care team if you cannot find an available slot
Author Contributions Conception and design: Lemonick, Venigalla, Nguyen, Ezzat, Schupper
When used thoughtfully, GLP 1 medications can help restore metabolic signaling that has become dysregulated due to aging, hormonal transitions, or years of dieting